ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of the company's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $57.19, for a total value of $14,297.50. Following the completion of the sale, the vice president now directly owns 56,488 shares in the company, valued at $3,230,548.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Meredith Cook also recently made the following trade(s):
- On Friday, September 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $56.82, for a total transaction of $14,205.00.
- On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.62, for a total transaction of $14,905.00.
ANI Pharmaceuticals Price Performance
ANIP stock opened at $58.60 on Wednesday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of 36.63 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81. The stock's fifty day simple moving average is $59.41 and its 200-day simple moving average is $62.55.
Trump or Kamala? It may come down to this strange twist…
From Porter & Company | Ad
Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia?
To uncover the full story and learn how you can potentially profit from it...
watch my new documentary here.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same period last year, the company earned $1.06 EPS. The firm's quarterly revenue was up 18.5% on a year-over-year basis. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on ANIP. Truist Financial reissued a "hold" rating and set a $60.00 price objective (down from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an "overweight" rating and a $68.00 price target for the company. Raymond James upped their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. StockNews.com cut ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Finally, HC Wainwright restated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $77.00.
View Our Latest Stock Analysis on ANIP
Institutional Investors Weigh In On ANI Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Innealta Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $65,000. Ridgewood Investments LLC purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth $85,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals in the first quarter valued at $106,000. O Shaughnessy Asset Management LLC purchased a new stake in ANI Pharmaceuticals during the first quarter valued at about $218,000. Finally, XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals during the second quarter worth about $207,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
